The main focus of the work will be the design, synthesis and construction of the TH-peptide constructs that are needed for cell-specific delivery of TH modulators in the various target cells. Pepscan will also bring its expertise in dissemination and commercialization of project results and help to bring positive pre-clinical results from the project into the next stages of development.
Prof. Peter Timmerman
Prof. Peter Timmerman was trained as a supramolecular chemist and was a former teacher in academics (Univ. Twente, 1995-2001). He is currently the Chief Scientific Officer of Pepscan and drives novel advances in the development of therapeutic peptides and also protein mimicry technology for therapeutic antibody and vaccine development. One of his achievements involves the development of a therapeutic vaccine against Vascular Endothelial Growth Factor (VEGF), which is currently in Phase-I/IIa clinical testing in humans at the VU Medical Centre in Amsterdam. Since March 2007 he holds a part-time professorship ("Protein Mimetic Chemistry") at the Faculty of Science of the University of Amsterdam (UvA) where he runs a small research group. He is a co-author of over 80 scientific articles.
Dr. Wim Schaaper
Dr. Wim Schaaper was trained as a peptide-chemist and has more than 30 years of experience in both solution- and solid-phase peptide synthesis, with a track record in (i) peptide-conjugates, and (ii) peptide-based vaccines. He is co-author of over 70 scientific articles and 7 patents.